Menu
Log in

FCACC logo

2026 continuing education creditS


annual meeting

Criteria for Success

Certificates of completion will be awarded based on the participant's attendance and completion of an online evaluation/claim credit form. If you have questions about this CE activity, please contact AKH Inc at JGoldman@akhcme.com.


Instructions for claiming CME/CE credit

 

1. To claim your CE credit, visit https://akhcme.com/flacc2026

2. Click Register/Take Course > Click Register (or Login if you've already created an account).

3. Click Get Started to continue to the evaluation, claim credit, and download your

Certificate of Completion.

 

Your certificate will remain available anytime under My Account > My Activities.

 

Please claim your credit by September 1, 2026.


Annual Meeting of the Florida Chapter ACC

Where Science Meets Patient Care

July 31- August 2, 2026 | Lake Buena Vista, FL

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare. 


In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and the Florida Chapter, American College of Cardiology. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Nurses

Credit being awarded: 7.0 ANCC contact hours

 

Pharmacists

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 7.0 contact hours.

 

Physician Associates

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

 


Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Florida Chapter, American College of Cardiology.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 7.0 contact hour(s) (which includes 3.5 hour(s) of pharmacology).

 

Commercial Support

There is no commercial support for this activity.


Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

 

Speaker, Instructor, Faculty(s)

Mahmoud Abdalla, MD has no relevant financial relationships to disclose at this time.

Fatemah Akbar, MD has no relevant financial relationships to disclose at this time.

Mohammad Al-mousily, MD has no relevant financial relationships to disclose at this time.

Carlos Alfonso, MD FACC FSCAI has a financial relationship (Speaker) with Boston Scientific; Zoll Medical; Johnson & Johnson.

Mays Ali, MD, FACC, FASE has a financial relationship (Advisor) with British Medical Journal: Best Practice.

Nitza Alvarez has no relevant financial relationships to disclose at this time.

Riyaz Bashir, MD, FACC has a financial relationship (Individual stocks and stock options) with Thrombolex Inc.

Thomas Beaver has a financial relationship (Consultant) with Merit; Edwards; Gore.

JAMIE LEE BORKOWSKI, Cardio-Oncology Advanced Provider has no relevant financial relationships to disclose at this time.

Katia Bravo Jaimes, MD has no relevant financial relationships to disclose at this time.

Katelyn Bruno, Katelyn Bruno, PhD, HFSA, FACC has no relevant financial relationships to disclose at this time.

Almudena Castro, MD, PhD, FESC has a financial relationship (Consultant) with Novartis; Novo Nordisk.

Madhavi Chunduru has no relevant financial relationships to disclose at this time.

Jennifer Co-Vu has no relevant financial relationships to disclose at this time.

Carlos Collet, MD, PhD has a financial relationship (Consultant) with Boston Scientific; Abbott Vascular; financial relationship (Speaker) with Medtronic; GE Healthcare; Siemens; Shockwave Medical; Heartflow; financial relationship (Royalties or patent beneficiary) with Coroventis.

Thais Coutinho, MD has no relevant financial relationships to disclose at this time.

Suraj Dahal, MD has no relevant financial relationships to disclose at this time.

Abdallah El Sabbagh, MD has no relevant financial relationships to disclose at this time.

Jude Elsaygh has no relevant financial relationships to disclose at this time.

IGNACIO FERNANDEZ LOZANO has no relevant financial relationships to disclose at this time.

Arnab Ghosh, Arnab Ghosh MD, MSc, MA has no relevant financial relationships to disclose at this time.

Patricia Guerrero, MD, CPE, FACC, FASPC has no relevant financial relationships to disclose at this time.

Sajjad Gul, Sajjad Gul has no relevant financial relationships to disclose at this time.

James Howick, MD has no relevant financial relationships to disclose at this time.

Joshua Hutcheson, PhD has no relevant financial relationships to disclose at this time.

Neelima Katukuri, MD, FACC, FSCAI has no relevant financial relationships to disclose at this time.

Danyal Khan, Pediatric & Adult Congenital Cardiologist has no relevant financial relationships to disclose at this time.

Priya Kothapalli, MD, FACC, FSCAI has no relevant financial relationships to disclose at this time.

Bridget Lee, DO has no relevant financial relationships to disclose at this time.

Jonathan Lopez, MD has no relevant financial relationships to disclose at this time.

Mario Lopez has no relevant financial relationships to disclose at this time.

Melissa Lyle has no relevant financial relationships to disclose at this time.

Carol Ma, MD FACC has no relevant financial relationships to disclose at this time.

Ajit Magadum has no relevant financial relationships to disclose at this time.

Fadi Matar, MD, FACC, FSCAI has no relevant financial relationships to disclose at this time.

William Miranda has no relevant financial relationships to disclose at this time.

Jose Nativi Nicolau, MD, MSc, FACC, FHFSA has a financial relationship (Researcher) with Alnylam; Alexion; Intellia; Novo Nordisk; Natera.

Alex Parker has no relevant financial relationships to disclose at this time.

Ricardo Pineda has no relevant financial relationships to disclose at this time.

Claudia Ponce Aportela, Ph. D Candidate in Biomedical Engineering has no relevant financial relationships to disclose at this time.

Jordan Ray, MD has no relevant financial relationships to disclose at this time.

Jose Rivas Rios has no relevant financial relationships to disclose at this time.

Joshua Saef, MD, MSc, FACC has no relevant financial relationships to disclose at this time.

Rhea Sancassani, MD, FACC has no relevant financial relationships to disclose at this time.

Yader Sandoval has a financial relationship (Consultant) with Abbott Vascular; Boston Scientific; CathWorks; Cleerly; GE Healthcare; Heartflow; IMDS; Philips; Roche Diagnostics; Siemens Healthineers;financial relationship (Speaker) with Medtronic.

Amy Sheer, MD MPH has a financial relationship (Speaker) with Novo Nordisk; Eli Lilly.

Shashank Sinha, Shashank S. Sinha, MD, MSc, FACC, FAHA, FHFSA has a financial relationship (Researcher) with J&J MedTech/Abiomed; Abbott.

Ryan Tedford, MD, FACC, FAHA, FHFSA has a financial relationship (Consultant) with Abbott; Acorai; Adona; Boston Scientific; CVRx; Endotronix; Edwards; Fauno Bio; Gradient; Imbria; Medtronic; Merck; Morphic Therapeutics; Pulmovant; Restore Medical; Tempus AI; 35Pharma; United Therapeutics; inhibikase; financial relationship (Researcher) with Abiomed; financial relationship (Individual stocks and stock options) with Aria CV.

Ufuk Vardar has no relevant financial relationships to disclose at this time.

Gabriella Vazquez, MSN, FNP-C has no relevant financial relationships to disclose at this time.

Davide Ventura, PharmD, BCCCP has no relevant financial relationships to disclose at this time.

Carlos Vergara Sanchez, MD has no relevant financial relationships to disclose at this time.

Jeffrey Williams, MD, MS, FACC, FHRS, HF-Cert has a financial relationship (Advisor) with Boston Scientific Corp; Parasym, Ltd.; financial relationship (Individual stocks and stock options) with Archer First Response, Inc.

David Wolinsky has a financial relationship (Advisor) with Bridge Bio; AstraZeneca; financial relationship (Consultant) with viz.ai; financial relationship (Speaker) with BridgeBio; Pfizer.

Malissa Wood, MD has no relevant financial relationships to disclose at this time.

Kenan Yount, MD MBA has a financial relationship (Consultant) with Medtronic; Edwards LifeSciences; Abbott.


Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.

 

If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.


Activity Overview

The cardiovascular team is an intricate part of any successful CV care setting, care givers must be up to date on the latest therapies and technologies.

 

Target Audience

This activity is designed for an audience of physicians, nurses, pharmacists, physician associates and nurse practitioners who treat and manage cardiovascular diseases.

 

Learning Objectives

Upon completion of the educational activity, participants should be able to:

 

Cardiogenic Shock 2025: From SUSPECT to Solutions 

  • Identify current evidence-based strategies for the early recognition and diagnosis of cardiogenic shock. 
  • Compare contemporary approaches to hemodynamic support and multidisciplinary shock management. 
  • Apply current evidence to improve outcomes for patients with cardiogenic shock. 

 

Seeing is Believing: CT-Guided Planning from Pixels to Procedures

  • Evaluate the role of computed tomography (CT) imaging in the assessment and treatment planning of patients undergoing cardiovascular interventions.

 

The Contemporary CTEPH Toolbox: Integrating BPA Into Multidisciplinary Care 

  • Describe current treatment options for chronic thromboembolic pulmonary hypertension (CTEPH). 
  • Evaluate patient selection criteria for balloon pulmonary angioplasty (BPA).
  • Incorporate multidisciplinary management strategies into the care of patients with CTEPH. 

 

Irwin R. Callen Memorial Lectureship: Right on Time—Rediscovering the Right Ventricle 

  •  Review the role of right ventricular structure and function in cardiovascular disease. 
  • Interpret current diagnostic approaches to right ventricular assessment. 
  • Integrate right ventricular evaluation into clinical decision-making. 

 

Hormones and the Heart: Navigating Cardiovascular Risk in Perimenopausal Women 

  • Recognize cardiovascular risk factors unique to perimenopausal women. 
  • Discuss the impact of hormonal changes on cardiovascular health. 
  • Apply evidence-based strategies to reduce cardiovascular risk in women during midlife.

 

Cross-Atlantic Perspectives: AICD Policy Insights From Spain 

  • Compare international approaches to implantable cardioverter-defibrillator (ICD) utilization. 
  • Discuss healthcare policy factors that influence device therapy. 
  • Identify opportunities to improve evidence-based ICD implementation. 

 

Aortic Function in Thoracic Aortic Aneurysms: Because the Aorta Is Not Just a Pipe 

  • Describe the relationship between aortic function and thoracic aortic aneurysm progression. 
  • Interpret emerging diagnostic methods for evaluating aortic disease. 
  • Apply current evidence to optimize management of patients with thoracic aortic aneurysms. 

 

Structural Valve Intervention in 2026: Decision-Making in the Gray Zones 

  • Evaluate patient selection for transcatheter valve interventions. 
  • Compare treatment strategies for multivalvular heart disease. 
  • Integrate guideline-directed medical therapy with structural heart interventions. 

 

Sociedad Española de Cardiología & FCACC Joint Session 

  • Review evidence supporting first-line atrial fibrillation ablation. 
  • Apply current lipid management recommendations for primary prevention. 
  • Compare optimal medical therapy and revascularization strategies for stable coronary artery disease. 

 

Cardio-Oncology 

  • Recognize cardiovascular complications associated with cancer therapies. 
  • Apply multidisciplinary strategies for cardiovascular risk assessment in oncology patients. 
  • Develop evidence-based management plans using case-based learning. 

 

EP Summit 

  • Interpret complex electrophysiology cases using current evidence. 
  • Evaluate emerging technologies and procedural approaches in cardiac electrophysiology. 
  • Apply advanced ECG interpretation to challenging clinical scenarios. 

 

Not All Thick Hearts are the Same: Clinical Challenges Across the Spectrum of HCM and Cardiac Amyloidosis

  • Differentiate the diagnostic, therapeutic, and disease-monitoring considerations for patients with hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis to support evidence-based clinical management.

 

Translational Research

  • Evaluate emerging translational research advances in cardiovascular disease.

 

Women Cardiologists: Own Your Narrative—Social Media Strategies for Women in Cardiology 

  • Describe best practices for professional engagement on social media. 
  • Identify strategies for effective professional branding and advocacy. 
  • Utilize digital platforms to enhance education, networking, and leadership opportunities. 

 

EKG in the Athlete: From Physiology to Policy—Navigating Florida's New Requirements 

  • Differentiate physiologic from pathologic ECG findings in athletes. 
  • Apply current recommendations for cardiovascular screening of athletes. 
  • Interpret Florida's evolving requirements for athletic ECG evaluation. 

 

When Winds Rise, So Do Heart Risks: Hurricanes and Heart Disease 

  • Describe the cardiovascular impact of natural disasters. 
  • Identify vulnerable patient populations during disaster events. 
  • Develop preparedness strategies to improve cardiovascular care during emergencies. 

 

Beyond the Basics: Practical Insights from the 2025 ACHD Guidelines 

  • Summarize key updates from the 2025 Adult Congenital Heart Disease guidelines. 
  • Apply guideline recommendations to common adult congenital heart disease scenarios. 
  • Optimize longitudinal care for adults with congenital heart disease. 

 

Great Debate: GLP-1 Receptor Agonists Are Cardiovascular Medications and Should Be Initiated by Cardiologists for Secondary Prevention 

  • Review current evidence supporting GLP-1 receptor agonists for cardiovascular risk reduction. 
  • Compare differing perspectives regarding clinician responsibility for initiating therapy. 
  • Incorporate shared decision-making when considering GLP-1 receptor agonists for secondary prevention. 

 

FL-QUIC Oral Presentations 

  • Evaluate quality improvement initiatives designed to improve cardiovascular care. 
  • Apply evidence-based strategies to optimize heart failure management and appropriate imaging utilization. 
  • Identify opportunities to implement quality improvement initiatives within their own practice. 

 

FIT Oral Presentations 

  • Assess emerging cardiovascular research presented by Fellows in Training. 
  • Discuss the impact of social media and epidemiologic trends on cardiovascular care. 
  • Translate novel research findings into future clinical practice and investigation.





Florida Chapter, American College of Cardiology
3208 E. Colonial Drive, Suite 264

Orlando, FL 32803

Contact Us

LinkedIn logo



Powered by Wild Apricot Membership Software